Sector News

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

May 15, 2022
Life sciences

The biggest biopharma acquisition of a drug company in 2021 has been delayed as antitrust reviews drag on.

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.

In its own statement, Vifor on Thursday said some antitrust authorities haven’t delivered a verdict. A Vifor spokesperson declined to specify which regulators remain undecided or whether any specific concerns have been raised. Rulings from the U.S. Federal Trade Commission, the European Competition Commission and the Swiss Takeover Board are all still pending, the Australia Financial Review reports.

Delays in the regulatory approval process are not unusual, Vifor noted. Vifor said the two firms are continuing to work with the remaining antitrust authorities, and CSL said it remains confident in completing the buyout.

Winning antitrust green lights represent the last hurdle in the Vifor acquisition. Back in March, CSL said (PDF) it had collected 74% of Vifor shares and therefore declared the tender offer successful. At the time, the Australian company said the antitrust review process was on track and it reconfirmed the mid-2022 deal closure timeline.

CSL has its eyes on Vifor’s kidney disease and iron deficiency offerings. CSL’s biotech business, CSL Behring, is currently heavily dependent on its immunoglobulin portfolio, which is facing some difficulties during the pandemic due to plasma collection constraints. Elsewhere, the company’s hereditary angioedema therapy Haegarda is under pressure from Takeda’s Takhzyro and BioCryst Pharma’s newly launched oral drug Orladeyo.

The Australian biotech also sells hemophilia B product Idelvion, and its hemophilia B gene therapy program, bought from uniQure, recently turned up positive results in a phase 3 trial.

Vifor itself had a setback since the CSL takeover’s announcement in December. The FDA recently rejected Akebia Therapeutics’ chronic kidney disease anemia therapy vadadustat. Vifor has a license to sell the drug through its Fresenius dialysis facilities and other third-party sites.

Vifor boasts 37 programs in development, which can give CSL’s own pipeline a 32% boost.

By Angus Liu

Source: fiercepharma.com

comments closed

Related News

July 3, 2022

Novo Nordisk joins with nursing group to highlight correlation between Type 2 diabetes and cardio risk

Life sciences

Despite atherosclerotic cardiovascular disease (ASCVD) being the leading cause of death for people with Type 2 diabetes, half of those people have no idea of this risk. Novo Nordisk has teamed up with the Preventive Cardiovascular Nurses Association (PCNA) for “Making the Connection,” a program to help increase understanding of the link between the two diseases.

July 3, 2022

First treatment for ‘broken heart syndrome’ trialled

Life sciences

The first ever treatment for broken heart syndrome – also known as Takotsubo cardiomyopathy – is to be trialled by researchers at the University of Aberdeen. Scientists will trial a programme of exercise conditioning and psychological therapy for people who have been diagnosed with the condition following a £300,000 grant from the British Heart Foundation.

July 3, 2022

Nestlé acquiring The Better Health Company in market expansion deal

Life sciences

Nestlé Health Science is set to acquire The Better Health Company (TBHC), as part of its goals to grow global market share while spurring innovation across the nutrition industry. The acquisition includes the GO Healthy brand with its vitamins and supplements, Egmont, the Manuka honey brand and New Zealand Health Manufacturing, an Auckland-based manufacturing facility for vitamins minerals and supplements.